[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 35 Engrossed in House (EH)]
H. Res. 35
In the House of Representatives, U. S.,
December 10, 2009.
Whereas as many as 3,000,000 Americans suffer from type 1 diabetes, a chronic,
genetically determined, debilitating disease affecting every organ
system;
Whereas more than 15,000 children each year are diagnosed with type 1 diabetes,
a disease caused by an autoimmune attack that destroys the insulin-
producing beta cells of the pancreas;
Whereas diabetes is one of the most costly chronic diseases, costing the United
States economy more than $174,000,000,000 and costing individuals with
diabetes an average of $13,000 in annual health care costs, compared to
$2,600 for individuals without diabetes;
Whereas insulin treats but does not cure this potentially deadly disease and
does not prevent the complications of diabetes, which include blindness,
heart attack, kidney failure, stroke, nerve damage, and amputations;
Whereas the National Institutes of Health has established 6 goal areas to guide
type 1 diabetes research focused on the reduction, prevention, and cure
of type 1 diabetes and its complications;
Whereas Federal funding has enabled research focused on determining the
underlying genetic and environmental causes of diabetes and testing of
promising new treatments to halt and reverse the autoimmune attack
causing type 1 diabetes;
Whereas a cure for type 1 diabetes will require restoring beta cell function
either by replacement with transplantation or by beta cell regeneration;
Whereas the development of a `closed-loop' artificial pancreas would greatly
alleviate the daily burden of disease management for type 1 diabetes
patients by continuously monitoring blood sugar levels, infusing insulin
as necessary when blood glucose levels become too high, and warning
patients when blood glucose levels become dangerously low;
Whereas continued progress toward a cure for type 1 diabetes depends on training
the next generation of diabetes researchers;
Whereas a strong public-private partnership to fund type 1 diabetes exists
between the Federal Government and the Juvenile Diabetes Research
Foundation International, a foundation which has awarded more than
$1,000,000,000 for diabetes research since its founding and in fiscal
year 2008 provided more than $156,000,000 for diabetes research in 20
countries;
Whereas Congress has provided $150,000,000 annually through fiscal year 2011 for
the Special Statutory Funding Program for type 1 Diabetes Research;
Whereas the National Institutes of Health devoted a total of $433,000,000 in
fiscal year 2009 for type 1 diabetes research;
Whereas leading type 1 diabetes researchers have recommended a total funding
level of $4,100,000,000 for fiscal years 2009 through 2013 in order to
meet the National Institutes of Health's type 1 research goals: Now,
therefore, be it
Resolved, That Federal funding for diabetes research should be increased to
meet the National Institutes of Health's goals so that a cure for type 1
diabetes can be found.
Attest:
Clerk.